학술논문
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
Document Type
Article
Author
Source
In: Annals of Hematology . (Annals of Hematology, July 2023, 102(7):1773-1787)
Subject
Language
English
ISSN
14320584
09395555
09395555